Xeljanz safety and effects in Korean children with juvenile idiopathic arthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational post‑marketing surveillance program in Korea monitoring pediatric patients prescribed Xeljanz for juvenile idiopathic arthritis for up to 44 weeks. Patients aged 2 to less than 18 who receive Xeljanz per approved labeling and investigator judgment are followed during their routine clinical visits to record safety events and treatment effects. The study is sponsored by Pfizer and collects real‑world data to supplement existing clinical trial evidence. Data collection focuses on adverse events, tolerability, and measures of disease control as observed in clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. Pediatric subjects aged from 2 years to less than 18 years
2. Xeljanz administered according to efficacy/effectiveness on the approved labeling
3. Patients who will administer Xeljanz based on the medical judgement of the investigator
4. Evidence of a personally signed and dated informed consent document indicating that the subject (and a legally acceptable representative) has been informed of all pertinent aspects of the study

Exclusion Criteria:

Subjects meeting any of the following criteria will not be included in the study:

1\) Subjects who are contraindicated from taking Xeljanz according to approved labeling\*

\*Refer to most recently approved label

Where it's running

• Pfizer
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCMA/CD70-directed CAR-T for children with hard-to-treat rheumatic diseases

  This trial will try a BCMA/CD70-directed CAR-T therapy in children aged 5 and older whose rheumatic diseases have not responded to standard treatments.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hangzhou, Zhejiang · NCT07184450

• Evaluating Deucravacitinib for Juvenile Psoriatic Arthritis in Children

  This study is testing if a new medication called Deucravacitinib can help children with juvenile psoriatic arthritis who haven't had success with other treatments.

  Recruiting at 29 sites Phase 3 Bristol-Myers Squibb · Lancaster, California and 47 other locations · NCT06869551

• Evaluating the safety and effectiveness of intravenous secukinumab in children with juvenile psoriatic arthritis.

  This study is testing if an intravenous medication called secukinumab is safe and effective for children with juvenile psoriatic arthritis.

  Recruiting at 11 sites Phase 1 Novartis · Loma Linda, California and 10 other locations · NCT06751238

• Evaluating Bimekizumab for Pediatric Arthritis

  This study is testing a new medication called bimekizumab in children with certain types of arthritis to see if it is safe and effective for them.

  Recruiting at 21 sites Phase 3 UCB Pharma · Calgary and 22 other locations · NCT06668181

• Assessing the safety and effectiveness of risankizumab and adalimumab in children with juvenile psoriatic arthritis

  This study is testing a new medication called risankizumab to see if it works better and is safer than the standard treatment adalimumab for children with juvenile psoriatic arthritis.

  Recruiting at 34 sites Phase 3 AbbVie · Little Rock, Arkansas and 33 other locations · NCT06100744

• Using Apremilast to treat oral ulcers in children with Behçet's disease or juvenile psoriatic arthritis

  This study is testing if the medication apremilast can safely help children with oral ulcers from Behçet's disease or juvenile psoriatic arthritis feel better over a longer time.

  Recruiting at 7 sites Phase 3 Amgen · Thessaloniki and 6 other locations · NCT05767047

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.